Heron Therapeutics Inc (HRTX) Receives Average Rating of “Buy” from Analysts

Heron Therapeutics Inc (NASDAQ:HRTX) has earned an average rating of “Buy” from the twelve ratings firms that are covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a sell rating, two have given a hold rating and eight have given a buy rating to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $55.50.

Several equities research analysts have recently weighed in on HRTX shares. BidaskClub upgraded shares of Heron Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Thursday, December 27th. Cantor Fitzgerald reiterated a “buy” rating and set a $50.00 price objective on shares of Heron Therapeutics in a research report on Monday, December 31st. ValuEngine upgraded shares of Heron Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, January 2nd. Zacks Investment Research cut shares of Heron Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, January 9th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $64.00 price objective (down from $66.00) on shares of Heron Therapeutics in a research report on Wednesday, January 16th.

NASDAQ HRTX traded up $0.78 on Monday, hitting $23.50. The company’s stock had a trading volume of 1,056,470 shares, compared to its average volume of 876,981. Heron Therapeutics has a 1-year low of $21.25 and a 1-year high of $42.90. The stock has a market cap of $1.84 billion, a P/E ratio of -9.63 and a beta of 1.55.

Heron Therapeutics (NASDAQ:HRTX) last announced its quarterly earnings results on Friday, February 22nd. The biotechnology company reported ($0.63) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.46) by ($0.17). Heron Therapeutics had a negative net margin of 230.84% and a negative return on equity of 54.98%. The business had revenue of $28.84 million during the quarter, compared to analyst estimates of $28.05 million. On average, analysts expect that Heron Therapeutics will post -1.52 EPS for the current year.

Several institutional investors and hedge funds have recently bought and sold shares of HRTX. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Heron Therapeutics by 24.3% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,747 shares of the biotechnology company’s stock worth $123,000 after acquiring an additional 929 shares in the last quarter. Jefferies Group LLC bought a new position in Heron Therapeutics during the third quarter worth $202,000. Verition Fund Management LLC bought a new position in Heron Therapeutics during the third quarter worth $208,000. Stephens Inc. AR bought a new position in Heron Therapeutics during the fourth quarter worth $208,000. Finally, Pacer Advisors Inc. bought a new position in Heron Therapeutics during the third quarter worth $223,000.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

Read More: Investing in Growth Stocks

Analyst Recommendations for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.